Literature DB >> 6404823

Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.

J D Klinger, H A Cash, R E Wood, J J Miler.   

Abstract

Rats were immunized systemically with various doses of the polyvalent Pseudomonas aeruginosa vaccine PEV-01. After a series of two or three doses (25 to 50 micrograms each) at 8- to 11-day intervals, animals were challenged intratracheally by the agarose bead technique with a serotype 5 P. aeruginosa strain at periods of 9 to 42 days. Immunized animals developed circulating antibodies (primarily immunoglobulin M) against vaccine components at levels significantly higher than challenged, nonimmunized controls (P less than 0.005). Eight to ten days postinfection, histological sections of lungs from immunized animals showed only minimal inflammation associated with infectious foci (agarose beads) as compared with the extensive pathological changes of airways and parenchyma seen in infected nonimmunized control animals. However, no significant reduction in bacterial numbers was observed. Such protection lasted at least 6 weeks after the final immunization. It is speculated that the vaccine may contain components of cell surface proteins and virulence exoproducts.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404823      PMCID: PMC348108          DOI: 10.1128/iai.39.3.1377-1384.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Immune complexes in cystic fibrosis.

Authors:  H McFarlane; A Holzel; P Brenchley; J D Allan; J C Wallwork; B E Singer; B Worsley
Journal:  Br Med J       Date:  1975-02-22

2.  THE IDENTIFICATION OF ATYPICAL STRAINS OF PSEUDOMONAS AERUGINOSA.

Authors:  A H WAHBA; J H DARRELL
Journal:  J Gen Microbiol       Date:  1965-03

3.  DTT test: a new method to differentiate IgM and IgG erythrocyte antibodies.

Authors:  B Pirofsky; E R Rosner
Journal:  Vox Sang       Date:  1974       Impact factor: 2.144

Review 4.  Burn wounds: microbiology, local host defenses, and current therapy.

Authors:  P Nathan; I A Holder; B G MacMillan
Journal:  CRC Crit Rev Clin Lab Sci       Date:  1973-07

5.  Immunization against Pseudomonas aeruginosa. I. Induction of protection by an alcohol-precipitated fraction from the slime layer.

Authors:  T H Alms; J A Bass
Journal:  J Infect Dis       Date:  1967-06       Impact factor: 5.226

6.  Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine.

Authors:  S Hanessian; W Regan; D Watson; T H Haskell
Journal:  Nat New Biol       Date:  1971-02-17

7.  Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.

Authors:  M Haghbin; D Armstrong; M L Murphy
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

8.  Exotoxins of Pseudomonas aeruginosa. 3. Characteristics of antitoxin A.

Authors:  P V Liu; H Hsieh
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

9.  Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.

Authors:  J W Alexander; M W Fisher; B G MacMillan
Journal:  Arch Surg       Date:  1971-01

10.  Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors.

Authors:  D R Schultz; K D Miller
Journal:  Infect Immun       Date:  1974-07       Impact factor: 3.441

View more
  6 in total

1.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

2.  Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain.

Authors:  G Reid; R C Chan; A W Bruce; J W Costerton
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

3.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

4.  Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific.

Authors:  L B Gilleland; H E Gilleland
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

5.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

6.  Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A.

Authors:  K W Klinger; C W Shuster; J Klinger
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.